Emergence of antimicrobial-resistant bacteria is an increasingly serious threat to global health, necessitating the development of innovative antimicrobials. We established a series of CRISPR-Cas13a-based antibacterial nucleocapsid, termed CapsidCas13a(s), capable of sequence-specific killing of carbapenem-resistant Escherichia coli and methicillin-resistant Staphylococcus aureus through promiscuous RNA cleavage after recognizing corresponding
antimicrobial resistance genes. CapsidCas13a constructs were generated by packaging CRISPR-Cas13a into a bacteriophage capsid to target antimicrobial resistance genes. Contrary to Cas9-based antimicrobials that lack bacterial killing capacity when the target genes are located on a plasmid, the CapsidCas13a(s) exhibited strong bacterial killing activities upon recognizing target genes regardless of their location. The antimicrobials' treatment efficacy was confirmed using a Galleria mellonella larvae model. Further, we demonstrated that the CapsidCas13a(s) can assist in bacterial gene detection without employing nucleic acid amplification and optical devices.
Main: The emergence and spread of antimicrobial resistance among pathogenic bacteria has been a growing global public health concern for several decades 1 . A recent nationwide survey of infectious disease specialists, conducted by the Emerging Infections Network of The Infectious Diseases Society of America, found that more than 60% of the participants attended to a patient with pan-resistant, untreatable bacterial infection within the previous year 2 . It is also predicted that antimicrobial-resistant (AMR) pathogens will cause 10 million fatalities per year by the year 2050 if new antimicrobial strategies are not developed 3 . In fact, the emergence 2 of AMR bacteria has led to the present post-antibiotic era, in which many currently available antimicrobials are no longer effective. This is due in part to the decline in antibiotic innovation, as no new class of antibiotics has been developed against Gram-negative bacteria in more than 45 years, and only a limited number of antibiotics was in either phase II or III clinical trial as of 2016 [https://www.edisongroup.com/edison-explains/antibiotics/]. Therefore, there is an urgent need for new strategies to develop alternative therapeutic approaches to prevent infections of AMR bacteria.
To this end, various nucleic acid-based antibacterials, novel peptides, bacteriophage therapies, antibodies, bacteriocins, and anti-virulence compounds have been recently developed 4 . Among these, CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9-encoding phages provide a means to combat such threats by selectively killing AMR bacteria. The CRISPR-Cas9 genome-editing construct, which is designed to target AMR genes, was packaged into phages to generate gene-specific antimicrobials. The resulting phage-mediated CRISPR-Cas9-based antimicrobials can be employed to selectively kill bacteria carrying targeted AMR genes 5 . However, even though the adaptability of CRISPR-Cas9 allows for the building of large libraries of CRISPR-Cas9-guided RNAs to act against rapidly evolving AMR bacteria, this strategy is ineffective against AMR bacteria carrying plasmid-encoded AMR genes, unless a lethal system, such as a toxin-antitoxin system, is also encoded by the plasmid because sole DNA cleavage does not simply result in bacterial death 6 .
CRISPR-Cas13a is the most recently identified CRISPR-Cas type VI class 2 system and is characterized by RNA-guided single-stranded RNA (ssRNA) cleavage activity 7, 8 . A 2016 study by Abudayyeh et al. demonstrated that CRISPR-Cas13a has promiscuous ssRNA cleavage activities and slows down the host bacteria growth due to degradation of host RNAs 8 . Our group recently reported the whole genome sequencing of 11 strains of six Leptotrichia species and analysis of the associated CRISPR-Cas13a systems showed that Leptotrichia shahii Cas13a (LshCas13a) had relatively high growth inhibition effect on host cells 9 , consistent with the observation in a previous study 8 . In order to understand whether this growth inhibition was due to cell death by Cas13a-mediated cytotoxicity, we constructed two phasmid systems (pKLC21 and pKLC26, see later) carrying CRIPSR-Cas13a and target gene, respectively, and co-introduced them into E. coli to test their effect on the host cells. We found that LshCas13a clearly showed target sequence-specific cell killing activity if the spacer was appropriately designed ( Supplementary Fig. 1 ). It opened a possibility that the CRISPR-Cas13a system can be applied for the development of new types of antimicrobials to cleave the mRNA of target genes regardless if the gene is encoded by the chromosome or plasmid, which might overcome the limitations of CRISPR-Cas9-based antimicrobials 6, 10, 11 . This possibility prompted us to explore the development of CRISPR-Cas13a-based antibacterial nucleocapsid, designated CapsidCas13a(s), which are expected to selectively kill bacteria that encode target genes on either the bacterial chromosome or plasmid. In order to determine if LshCas13a cleavage of ssRNA is sufficient to kill target bacteria, LshCas13a and a minimal CRISPR array containing one spacer were inserted into the plasmid pC003 to generate the plasmid pKLC21, which thus was programed to target the carbapenem resistance gene bla IMP-1 . The resulting pKLC21_bla IMP-1 construct was transformed into E. coli NEB5α F´l q cells with or without bla IMP-1 expression using pKLC26. Growth of the bla IMP-1 -expressing transformant was significantly inhibited, as compared to those without bla IMP-1 expression ( Fig. 1a ). Similar growth arrest was also observed in other E. coli cells transformed with a series of pKLC21 plasmids programed to target various carbapenem and colistin resistance genes, as well as other genes of interest ( Supplementary  Fig. 1 ). We interpreted these results as demonstrating CRISPR-Cas13a-mediated sequencespecific killing of antimicrobial-resistant E. coli. Following verification of the bactericidal activity of the CRISPR-Cas13a_bla IMP-1 construct against bla IMP-1 -positive bacteria, AMR bacteriaspecific CapsidCas13a constructs were developed by loading the CRISPR-Cas13a system onto a phage capsid. As an initial attempt, CRISPR-Cas13a_bla IMP-1 was loaded onto E. coli phage M13 capsid, which can infect F pili-positive E. coli, to generate EC-CapsidCas13a_bla IMP-1 ( Fig. 1b) , which demonstrated sequence-specific killing activity against bacteria carrying the bla IMP-1 gene in an EC-CapsidCas13a_bla IMP-1 concentration-dependent manner ( Fig. 1c ).
Subsequently, the same sequence-specific killing activities were confirmed with a series of CapsidCas13a constructs programmed to target different AMR genes, including those conferring resistance to carbapenem (bla IMP-1 , bla OXA-48 , bla VIM-2 , bla NDM-1 , bla KPC-2 ) and colistin (mcr-1, mcr-2), all of which are the representatives of currently problematic genetic factors in the clinical setting ( Fig. 1d ). Conversely, non-targeting CapsidCas13a killed no bacteria under any circumstance, indicating that this construct has ideal potential for gene-directed antimicrobial therapy against AMR bacterial infections.
A Cas9-based EC-CapsidCas9_bla NDM-1 construct was also generated with the same protocol, but in this instance, CRISPR-Cas13a_bla NDM-1 was replaced with CRISPR-Cas9_bla NDM-1 and its bacteria-killing manner was compared with that of EC-CapsidCas13a_bla NDM-1 . As expected, EC-CapsidCas9_bla NDM-1 killed only the bacteria with a chromosomal target gene, while EC-CapsidCas13a_bla NDM-1 killed the bacteria that carried the target gene on either the chromosome or plasmid ( Fig. 1e ). Since the majority of clinically important AMR genes are encoded on plasmids 12 , the killing efficiency of CapsidCas13a was expected to be superior to that of CapsidCas9 in light of the current difficulty with the threat of Carbapenem-resistant Enterobacteriaceae (CRE) carrying resistant genes on the plasmids. Besides, previous studies have suggested that CRISPR-Cas9 is prone to unexpected genetic mutations due to its DNAcleavage activity 13, 14, 15 . On the contrary, instead of DNA, CapsidCas13a targets RNA; therefore, unintended evolution of the bacteria is unlikely.
In order to determine whether the CapsidCas13a(s) can selectively kill target bacteria among a mixed population of AMR bacteria, an artificial mixture of E. coli NEB5α F'I q expressing the carbapenem resistance gene bla IMP-1 , the colistin resistance gene mcr-2, or with no resistance gene, as a control, was treated with each gene-specific EC-CapsidCas13a construct (i.e., EC-CapsidCas13a_bla IMP-1 and EC-CapsidCas13a_mcr-2, respectively). Subsequently, the abundance of each bacterial strain was determined. As shown in Fig. 2a , the percentage of cell numbers of NEB5α F'I q (bla IMP-1 ) and NEB5α F'I q (mcr-2) were significantly decreased from 30.5% and 35% to 3.5% and 1.9%, respectively, as a result of eradicating the target cells, when the cell mixtures were treated with EC-CapsidCas13a_bla IMP-1 and EC-CapsidCas13a_mcr-2, respectively, while there was no change in the abundance of cell populations after treated with non-targeting EC-CapsidCas13a_null control. These highly selective killing activities of CapsidCas13a(s) demonstrate their potential as microbial control agents that can modify or manipulate the bacterial flora without affecting undesired bacterial populations by eliminating those with specific genomic contents. In addition to demonstration of the versatility of CapsidCas13a, we investigated its in vivo therapeutic efficacy using a G. mellonella larvae infection model. Administration of EC-CapsidCas13a_bla IMP-1 to G. mellonella larvae infected with E. coli R10-61 carrying bla IMP-1 showed significantly improved survival over no treatment (p = 0.0016) or a non-targeting CapsidCas13a_null, as a control (p = 0.044) ( Fig. 2b ). This outcome further strengthened the therapeutic prospects of the CapsidCas13a constructs for treatment of infections with AMR bacteria.
Owing to the fact that the prevalence of stealth bacteria (carrying AMR genes but not identifiable by existing susceptibility tests) has been increasing 16 , the establishment of a simple and easy-to-use detection method for such strains at the genetic level is an important task in the clinical setting. Our results demonstrated that the CapsidCas13a(s) could be applied for the detection and identification of AMR genes. To this end, the CapsidCas13a constructs were modified for the detection of bacterial AMR genes. First, the spacer sequence of EC-CapsidCas13a_bla IMP-1 targeting the bla IMP-1 gene was optimized in order to improve the killing efficiency, since the bactericidal activity of CRISPR-Cas13a differed greatly depending on the spacer sequences ( Supplementary Fig. 1 ). The optimization started with the construction of a CRISPR-Cas13a expression plasmid library, in which 121 different spacer sequences targeting bla IMP-1 were inserted into the CRISPR array. Then, all plasmids were transformed into bla IMP-1expressing E. coli cells and the resulting transformants were analyzed to identify the most effective spacer sequence ( Supplementary Fig. 2a ). The calculation of the number of spacer reads after deep sequencing of the total plasmid DNAs extracted from the transformants found that all of the tested spacer sequences mediated target-specific bacterial killing, at least to some extent, when judged by the depletion efficiency of the plasmid DNAs ( Supplementary Fig.  2b and Supplementary Table 4 ). Among these, 13 spacer sequences had depletion efficiencies of >100 and the bla IMP-1 -563 spacer sequence GACTTTGGCCAAGCTTCTATATTTGCGT, which had the highest depletion efficiency of 364.1 was chosen as the best spacer sequence for use in subsequent experiments ( Supplementary Fig. 2c ). Then, the carrier M13 phage was replaced with the capsid of lysogenic phage Φ80 with the use of the PICI (phage-inducible chromosomal island) packaging system 17, 18 (Fig. 3a and Supplementary Fig. 3 ). The M13 phage capsid described in the previous experiment was less than ideal for clinical applications since it can only infect bacteria carrying F pili. Finally, the kanamycin resistance gene KanR was inserted as a selection marker to generate the PICI-based EC-CapsidCas13a::KanR_bla IMP-1 construct, which was expected to have improved detection sensitivity. A simulation to test the detection efficiency for bla IMP-1 was conducted by spotting 25 µL of 10-fold serial dilutions of EC-CapsidCas13a::KanR_bla IMP-1 onto fresh top agar lawns of the test strains in LB agar with 5 or without supplementation of kanamycin. To judge the results, we opted to determine the bacterial killing effect against kanamycin-resistant cells on kanamycin plates ( Fig. 3b ), rather than assessing the bacterial killing effect against original cells on kanamycin-free plates ( Fig.  3c ). When the EC-CapsidCas13a::KanR_bla IMP-1 carrying the kanamycin-resistance gene was applied on the soft agar bacterial lawn grown on bottom agar containing kanamycin, the cells infected by this capsid acquired kanamycin resistance and, hence, could grow in the presence of kanamycin. Nevertheless, with the bacterial cells carrying the target AMR gene bla IMP-1 , there was no observable growth due to the bactericidal effect of the CRISPR-Cas13a construct (Fig.  3b ). This method was shown to be about 1,000 times more sensitive than direct observation of bacterial growth inhibition, as with the previous method ( Fig. 1c,d and 3c ). The efficiency of this system was also confirmed with the use of the M13 capsid-based EC-CapsidCas13a::KanR_bla IMP-1 construct ( Supplementary Fig. 4a -c). A subsequent experiment showed that the target AMR genes of interest located on either the plasmid or chromosome could be precisely detected, demonstrating that the AMR bacteria could be identified by this method (Fig. 3d ,e and Supplementary 4d,e). This finding was further confirmed by two other EC-CapsidCas13a::KanR constructs targeting bla OXA-48 and bla VIM-2 ( Fig. 3d ,e and Supplementary   Fig. 4d,e ). Although the sensitivity was slightly lower, it was even possible to detect target genes by directly spotting the CapsidCas13a(s) onto the bacteria swabbed on an agar plate instead of using the soft agar overlay method ( Supplementary Fig. 5 ). The CapsidCas13a(s) could also simultaneously detect the toxin-encoding genes stx1 and stx2 ( Fig. 3f ), indicating that this method is applicable for the detection of any bacterial gene.
Next, the applicability of the CapsidCas13a constructs for identification of carbapenemresistant clinical isolates of E. coli carrying bla IMP-1 or bla NDM-1 was tested. As these strains were not susceptible to kanamycin, the KanR of EC-CapsidCas13a::KanR was replaced with the hygromycin resistance gene, HygroR, to generate the constructs EC-CapsidCas13a::HygroR_bla IMP-1 and EC-CapsidCas13a::HygroR_bla NDM-1 . The test results with these two CapsidCas13a(s) showed that the E. coli isolates carrying bla IMP-1 and bla NDM-1 were clearly detected, which was consistent with the results of polymerase chain reaction (PCR) analysis ( Fig. 3g ). So far, there have been amazing developments of novel methods to detect bacterial genes, such as in situ hybridization, allele-specific PCR, loop-mediated isothermal amplification, endonuclease cleavage, direct DNA sequencing, primer extension, and oligonucleotide ligation. All these methods have unique merits in terms of sensitivity, accuracy, and robustness, allowing the wide use of each, but all have serious drawbacks that have often reduced general use. An intrinsic limitation to these molecular methods is that all are based on nucleic acid (DNA or RNA) amplification technology, which requires the use of expensive reagents as well as substantial operating costs. Reagents, disposable materials (e.g., PCR reaction tubes and pipette tips), thermal cyclers, and the necessary gel electrophoresis equipment are fairly expensive. In contrast, the proposed detection system using the CapsidCas13a constructs can be performed without amplification of DNA or RNA, electrophoresis equipment, or optical devices, as only bacterial culture plates are required. In addition, more than 10 10 transducing forming units (TFU) of CapsidCas13a constructs can be harvested per liter of host bacterial culture, although only 2-3 µL of 10 5 constructs per mL of solution is required for a single spot test to accurately determine the presence or absence of target genes. Together, these features highlight the elegant potentials of CapsidCas13a(s) for bacterial gene detection.
Lastly, in addition to demonstrating the bactericidal activity of CRISPR-Cas13a against Gramnegative bacteria, we also attempted to confirm the collateral activity of CRISPR-Cas13a against Gram-positive bacteria using Staphylococcus aureus. At first, a set of E. coli-S. aureus shuttle vectors, namely pKCL4(s), were generated carrying the CRISPR-Cas13a construct with or without a spacer sequence targeting the S. aureus rpsE genes. Transformation of the vector into S. aureus strain RN4220 showed that the bactericidal activity of CRISPR-Cas13a with an appropriate spacer sequence was similar to that in E. coli ( Supplementary Fig. 6a ).
Then, a SA-CapsidCas13a_mecA construct was produced to target methicillin-resistant gene mecA of methicillin-resistant S. aureus (MRSA), one of the most prevalent AMR pathogens worldwide 19 . Optimization of the spacer sequences ( Supplementary Fig. 6b -e) and the CRISPR-Cas13a_mecA carrying vector (pKCL-SP_mecA) construction were carried out in the same way as above for CRISPR-Cas13a_bla IMP-1 , and packing of CRISPR-Cas13a_mecA into S. aureus phage Φ80α capsid was performed in accordance with the method established by Carles Ubeda et al. using the S. aureus pathogenicity island (SaPI) system 20, 21 ( Supplementary   Fig. 7 ). This packing system simultaneously imparted tetracycline resistance to the resulting SA-CapsidCas13a::TetR_mecA construct, since the SaPI carried the tetracycline resistance gene, which made it possible to be tested for both bacterial killing ability against MRSA and capability of MRSA detection by targeting mecA. As expected, when the methicillin-susceptible S. aureus (MSSA) strain RN4220 and MRSA USA300 or mecA knockout USA300 (USA300-ΔmecA) was infected with SA-CapsidCas13a_mecA, the growth of only the USA300 strain carrying mecA was significantly inhibited ( Fig. 3h and Supplementary Fig. 8 ), clearly demonstrating the sequence-specific bacterial killing ability of CRISPR-Cas13a against the Gram-positive bacteria S. aureus.
In this study, the promiscuous RNA cleavage ability of CRISPR-Cas13a via recognition of target RNA by CRISPR-RNA (crRNA), which resulted in host cell death, was exploited to generate a new type of sequence-specific bacterial antimicrobials. To deliver the CRISPR-Cas13a to target bacteria, the CRISPR-Cas13a was packaged into carrier phage capsid using PICI packaging system. Since synthesized CapsidCas13a does not carry phage-derived genes, thereby not being able to replicate in the infected bacteria, it can be considered to be safer than genetically modified phages as being used for therapeutic. Although there are still many questions to be answered concerning the host range of the phage capsids, catalytic mode of Cas13a 22 , the efficiency of phage capsid packaging, and ethical issues regarding genetic recombinants, etc., our strategy demonstrated that CRISPR-Cas13a-based antimicrobials, CapsidCas13a(s), are likely to be developed for at least three application categories: (1) promising antibacterial therapeutic agents targeting any bacterial gene, including AMR genes, or selective killing of targeted toxin-producing bacteria; (2) a simple and inexpensive bacterial gene detection system for bacterial identification and efficient molecular epidemiological investigations without the need for the amplification of nucleic acids or optic devices; and (3) tools to manipulate the bacterial flora by targeting and eliminating a specific bacterial population without disruption to other irrelevant bacterial populations. In conclusion, the proposed CRISPR-Cas13a-based antimicrobials are expected to have a great impact in the field of antimicrobial resistance, infection control as well as bacterial flora control. CRISPR-Cas13a_bla IMP-1 packaged onto E. coli M13 phage capsid (EC-CapsidCas13a_bla IMP-1 ) was delivered into the host bacterial cells. In the presence of the target gene (bla IMP-1expressing E. coli), CRISPR-Cas13a was activated and the subsequent non-sequence-specific RNase activity resulted in host cell death. On the other hand, E. coli cells without the bla IMP-1 gene were unaffected. c, EC-CapsidCas13a-bla IMP-1 triggered cell death or growth inhibition only when the target cells expressed bla IMP-1 (L-arabinose induction). d, CapsidCas13a(s) programmed to target specific carbapenem resistance genes (bla IMP-1 , bla OXA-48 , bla VIM-2 , bla NDM-1 , and bla KPC-2 ) and colistin resistance genes (mcr-1 and mcr-2) selectively killed only the bacteria harboring the corresponding resistance gene(s), as demonstrated by plaque formation. e, Unlike the CRISPR-Cas9 system, the CRISPR-Cas13a system selectively killed bacterial cells carrying target genes on the chromosome as well as the plasmid. Conversely, the activity of the CRISPR-Cas9 system was restricted only to the target gene located on the chromosome. 
Methods: Bacterial strains and culture conditions
Bacterial strains used in this study are listed in Supplementary Table 1 . Bacterial strains were grown at 37°C in Luria-Bertani (LB) medium (BD Difco). Unless otherwise indicated, proper antibiotics were added to growth medium to the following final concentrations: 100 µg/mL for ampicillin (Amp), 30 µg/mL for kanamycin (KM), 34 µg/mL for chloramphenicol (CP), 4 µg/mL for colistin, and 200 µg/mL for hygromycin (Hygro).
Construction of CRISPR-Cas13a vectors targeting various genes
The CRISPR-Cas13a expression vector (pC003), which carries LshC2c2 locus on pACYC184, was kindly provided by Dr. Feng Zhang (Addgene plasmid # 79152; http://n2t.net/addgene: 79152; RRID: Addgene_79152). In order to generate an efficient vector series that carry CRISPR-Cas13a system targeting various genes, the following vector manipulations were conducted. At first, a DNA fragment of cas13a-cas1-cas2 locus was amplified from Leptotrichia shahii strain JCM16776 9 using primer set of LsCas13a clo-f and LsCas13a clo-r (Supplementary Table 3 ), and another DNA fragment from the pC003 vector was also amplified using primers pC003 PCR-r and pC003 PCR-f. The two DNA fragments were then ligated with In-Fusion HD Cloning kit (TaKaRa Bio Inc., Japan) to generate pKLC5, which resulted in the replacement of cas13a-cas1-cas2 locus of pC003 with that of JCM16776. Next, the cas1-cas2 locus was removed from the pKLC5, because Cas1/2 is not necessary for bactericidal activity of CRISPR-Cas13a. It was achieved by performing PCR on the pKLC5 using primer set of Cas1 Cas2 del SacI-f and Cas1 Cas2 del SacI-r, digesting the PCR fragment with SacI (TaKaRa Bio Inc., Japan) and ligating again with Ligation high ver. 2 (Toyobo Co., Ltd, Japan) to generate pKLC5 ΔCas1/2. Following this, in order to allow the pKLC5 ΔCas1/2 being capable to be packaged into M13 phage capsid, f1 origin together with KM resistance gene (KanR) were inserted as follows: The f1 origin and the KanR were amplified from pRC319, a gift from Timothy Lu (Addgene plasmid # 61272; http://n2t.net/addgene: 61272; RRID: Addgene_61272), using primer set of InF13 pRC319-f and InF13 pRC319-r, and another primer set of InF13 PCR SalI-f and InF13 PCR SmaI-r was used to amplify vector part from the pKLC5 ΔCas1/2 vector. The resulting two DNA fragments were then ligated with In-Fusion HD Cloning Kit to generate pKLC21 that carries complete CRISPR-Cas13a system, except for leaving the cloning site empty for insertion of appropriate spacer if necessary. The pKLC21 carries f1 origin of M13 phage thus is able to interact with M13 phage. Finally, CRISPR-Cas13a system targeting carbapenem-resistant gene bla IMP-1 was constructed on the pKLC21 vector as follows: Briefly, 33 mer oligo DNAs (28 mer of spacer and 5 mer for inserting BsaI cut site) of blaIMP-1_104-s and blaIMP-1_104-as, corresponding to nucleotide position of bla IMP-1 from No. 104 to No. 132, were synthesized and annealed in annealing buffer [10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM EDTA]. After that, pKLC21 was treated with restriction enzyme BsaI-HF, gel-purified and subsequently ligated with the annealed oligo DNA using Ligation high ver.
2 to obtain pKLC21_bla IMP-1 _104. Likewise, a series of pKLC21 vectors targeting other carbapenem resistance genes (bla NDM-1 , bla KPC-2 , bla OXA-48 , bla VIM-2 ), colistin resistance genes (mcr-1, mcr-2), as well as mecA, rpsE, and ermC of S. aureus were produced. The bla IMP-1targting pKLC21 vector library covering the whole sequences of bla IMP-1 were also constructed in the same manner, whereby a total of 121 different oligo DNAs pairs covering the whole bla IMP-1 were inserted into the BsaI site of pKLC21. The sequences of all oligo DNAs used were listed in the Supplementary Table 3 .
Apart from pKLC21 vector series, S. aureus-E. coli shuttle vector carrying CRISPR-Cas13a (pKLC3.0) was also constructed. For the assembly of pKLC3.0, three DNA segments, KanR (aphA-3) and ori of E. coli, cat and p15A ori of S. aureus, and cas13a were amplified from plasmids pHel3, pDB114 (kindly provided by Dr. Luciano Marraffini) and pKLC21, respectively, using the following primer sets (Supplementary Table 3 
Construction of target gene expression vectors
In this study, two plasmid systems for expression of target genes of CRISPR-Cas13a systems were constructed: pSP72 aTc-inducible vector in which the cloning site for target gene expression was under the control of anhydrotetracycline (aTc); and pKLC26 that does not contain f1 origin of replication from M13 phage. For the construction of pSP72, aTcregulatory element was first amplified from pC008 vector using TetReg SalI-f and TetReg BamHI-r primers, and the amplicon was digested with restriction enzymes SalI and BamHI. After digestion, the fragment was inserted into SalI-BamHI site of pSP72 vector (Promega Corporation, US) carrying pBR322 origin and the resulting plasmid was termed pSP72 aTcinducible vector because cloning site (BamHI/EcoRI) for expression of target gene is regulated by aTc-inducible promotor. The pC008 (pBR322 with Tet-inducible RFP) was a gift from Feng Zhang (Addgene plasmid # 79157; http://n2t.net/addgene: 79157; RRID: Addgene_79157). A subsequent set of vectors expressing target genes for CRISPR-Cas13a were produced by cloning AMR genes (e.g. bla IMP-1 , bla NDM-1 , bla KPC-2 , bla OXA-48 , bla VIM-2 ) on the BamHI/EcoRI site of the generated plasmid.
The pKLC26 was constructed basically by modifying pBAD33 with deletion of f1 origin and ARA-promoter. Firstly, pBAD33 vector was amplified with two primers, pBAD33 PCR XhoI-f and pBAD33 PCR XhoI-r, which were designed to exclude f1 origin. After digestion with restriction enzyme XhoI, the fragment was self-ligated with Ligation high ver. 2 to generate pKLC23. Then, the pKLC23 vector and bla IMP-1 native promoter sequence (1,716-1,168 bp of GenBank ID: AB733642.1 artificially synthesized by GENEWIZ) were independently amplified with two primer sets, pKLC23 PCR InFusion-f2 and pKLC23 PCR InFusion-r2, and InFusion-f and Intl1pro InFusion-r, respectively. Combination of the resulting two fragments with In-Fusion HD cloning kit finally generated pKLC26 vector, which carries bla IMP-1 native promoter in replacement of ARA-promoter.
To obtain pKLC26_bla IMP-1 for bla IMP-1 expression, two PCR amplifications were carried out, generating fragment of pKLC26 using a primer pair InF18 pKLC26-f and InF18 pKLC26-r, and fragment of bla IMP-1 (GenBank ID: S71932) using a primer pair InF18 IMP-1-f and InF18 IMP-1-r. The two DNA fragments were then ligated with In-Fusion HD Cloning Kit to yield pKLC26_bla IMP-1 . By using the same method, a series of vectors for expression of the following AMR genes were generated (Supplementary Table 2 ): bla NDM-1 (GenBank ID: FN396876), bla KPC-2 (GenBank ID: AY034847), bla VIM-2 (GenBank ID: AF191564), bla OXA-48 (GenBank ID: AY236073), mcr-1 (GenBank ID: KP347127), mcr-2 (GenBank ID: LT598652) and rfp (encoding Red Fluorescent Protein, GenBank ID: KJ021042). The expressions of cloned genes were confirmed by susceptibility test against corresponding antibiotics using disk diffusion test recommended by CLSI.
Generation of M13 phage-based EC-CapsidCas13a
At first, to prevent M13 phage genome from self-assembly, the f1 origin of replication of helper phage M13KO7 (New England Biolabs, US) was deleted. This was achieved by performing PCR on M13KO7 plasmid using primer pair of M13KO7 PCR InFusion-f and M13KO7 PCR InFusion-r, and subsequently ligating resulting fragment with another PCR product carrying p15A origin and CP resistance gene, which was amplified from pBAD33 using primer pair of pBAD33 PCR InFusion-f and pBAD33 PCR InFusion-r. The ligation was performed with In-Fusion HD Cloning Kit and the resulting phagemid was termed pKLC25. Next, CRISPR-Cas13aloaded E. coli M13 phage capsid targeting bla IMP-1 (M13 phage-based EC-CapsidCas13a_bla IMP-1 ) was generated as follows: pKLC25 vector was transformed into E. coli MC1061 to synthesize helper phage (phage capsid). The transformed bacteria were selected on CP plates. Subsequently, the E. coli harboring pKLC25 was transformed with pKLC21 that carries CRISPR-Cas13a and f1 origin of M13 (i.e. pKLC21_bla IMP-1 vector) and selected on the LB agar containing CP and KM. The colonies grown on this double antibiotic selection plate were picked and cultured in LB liquid medium containing CP and KM at 37°C. E. coli cultures at stationary phase were then centrifuged at 8,000 g for 20 minutes and the supernatant was passed through a 0.22 µm filter. Equal volume of PEG buffer [5 mM Tris-HCl (pH 7.5), 10% PEG 6000, 1 M NaCl (58 g/L), 5 mM MgSO 4 ·7H 2 O (1.23 g/L)] was added to the filtrate, mixed well and left at 4°C for 24 hours. After that, mixtures were centrifuged at 12,000 g for 10 minutes at 4°C to pellet the M13 phage-based EC-CapsidCas13a_bla IMP-1 . To improve its purity, repeated centrifugation was carried out. Eventually, SM buffer [50 mM Tris-HCl (pH 7.5), 0.1 M NaCl, 7 mM MgSO 4 ·7H 2 O, 0.01% gelatin] was added and the pellet was resuspended to generate a final solution of the M13 phage-based EC-CapsidCas13a_bla IMP-1 . A series of M13 phage-based EC-CapsidCas13a(s) targeting the genes of bla NDM-1 , bla KPC-2 , bla VIM-2 , bla OXA-48 , mcr-1, mcr-2 and rfp were also prepared by using the same methods.
Generation of PICI-based EC-CapsidCas13a and EC-CapsidCas9
The E. coli JP12507 18 , derived by lysogenizing phage Φ80 into E. coli 594 strain, was used for the generation of PICI-based EC-CapsidCas13a(s). In order to prevent Φ80 from being self-packaged during generation of PICI-based EC-CapsidCas13a, cosN site necessary for phage DNA packaging was deleted to create JP12507ΔcosN. By using JP12507ΔcosN and series of PICImid pKLC31s, PICI-based EC-CapsidCas13a(s)::KanR targeting various genes were generated as follows. At first, the pKLC31_bla IMP-1 was transformed into JP12507ΔcosN, and the transformants were cultured on KM-containing LB plates. Then, several colonies were isolated and further cultured at 37°C with shaking in LB liquid medium containing KM together with adding mitomycin C for induction of prophage excision and L-arabinose for induction of ppi (for phage DNA packaging). The L-arabinose was added to a final concentration of 0.2% that allowed to reach its final concentration of 2 µg/mL when the bacteria culture reached to OD 600 of 0.1. The cultures were incubated overnight at 30°C with shaking at 80 rpm. After incubation, the supernatant was harvested and passed through a 0.22 µm filter. Same amount of PEG buffer was then added and the solution was left at 4°C for 1 hour after mixed well.
Then, the solution was centrifuged at 12,000 g for 10 minutes at 4°C, resulting in precipitation of PICI-based EC-CapsidCas13a::KanR_bla IMP-1 . To remove residual liquids, the pellet was washed several times and finally resuspended in SM buffer for further use. A series of PICIbased EC-CapsidCas13a::KanR(s) targeting the genes of bla NDM-1 , bla KPC-2 , bla VIM-2 , bla OXA-48 , mcr-1, mcr-2 and rfp were also prepared by using the same methods.
The PICI-based EC-CapsidCas13a::HygroR carrying Hygro resistance gene hygroR instead of KM-resistant gene kanR was generated by using plasmid pKLC44 in which kanR was 13 placed by hygorR. The pKLC44 was constructed by cutting the pKLC31 with SacI and XhoI and combining it with hygroR amplified from pKLC26 HygroR with primer pair of InF44 pKLC42f and InF44 pKLC42-r using In-Fusion HD Cloning Kit.
PICI-based EC-CapsidCas9 targeting bla NDM-1 (EC-CapsidCas9_bla NDM-1 ) was generated using JP12507ΔcosN strain and plasmid pKLC27 (carrying CRISPR-Cas9_bla NDM-1 and packaging site cosN rppA. The pKLC27 was constructed as follows. The CRISPR-Cas9_bla NDM-1 was amplified from the pCR319 (a gift from Timothy Lu) 6 using primer set of InF27 pRC319f and InF27 pRC319-r, and packaging site cosN rppA was amplified from pBAD18 cosN rppA using primers of InF27 araCosPPi-f and InF27 araCosPPi-r. The two amplicons were then ligated with In-Fusion HD Cloning Kit to generate pKLC27.
Generation of SaPI-based SA-CapsidCas13a_mecA
The SaPI-based SA-CapsidCas13a_mecA was generated basically using SaPI (Staphylococcus aureus pathogenicity island) packaging system 11, 21 . At first, the S. aureus-E.coli shuttle vector pKLC-SP_mecA carrying CRISPR-Cas13a_mecA targeting mecA of MRSA and control vector pKLC-SP_null were individually transformed into S. aureus strain RN4220-Φ80 -∆terS-SaPIbov2::tetM 20,23 by electroporation using NEPA21 electroporator (Nepa Gene Co., Ltd., Japan) with the following parameters: Poring Pulse (Voltage: 1,800 V, Pulse length: 2.5 msec, Pulse interval: 50 msec, Number of pulse: 1, Polarity: +), Transfer Pulse (Voltage: 100 V, Pulse length: 99 msec, Pulse interval: 50 msec, Number of pulse: 5, Polarity: ±). The resulting transformants were then recovered at a temperature permissive for the plasmid replication (28°C) for 1 hour and plated on tryptic soy agar (TSA) plates supplemented with 10 µg/mL CP. The plasmid can be integrated into the chromosome by homologous recombination when the transformants were incubated at 37°C (non-permissive temperature) in the presence of CP. Single colonies (from 37°C plate) were then inoculated into tryptic soy broth (TSB) and incubated at 28°C without antibiotic selection to stimulate rolling cycle replication. Finally, 100 µl of the 10 -5 dilution of this culture is plated on TSA with 1 µg/mL anhydrotetracycline to select for cells free of plasmid. Insertion of both CRISPR-Cas13a systems are validated by PCR. Finally, resulting cells were chemically induced by mitomycin C to generate SA-CapsidCas13a_mecA and SA-CapsidCas13a_null (control) by using the method described elsewhere 11 .
Generation of E. coli strain carrying foreign gene on its own chromosome Generation of E. coli strain that express foreign gene on its own chromosome was carried out by using ARA-inducible Red recombination system. To this end, at first, we transformed E. coli strains NEB 5-alpha F'l q (New England Biolabs, US) and MC1061 with plasmid pKD46 which carries ARA-inducible Red recombination system 24 . Next, the desired genes, e.g. bla IMP-1 , were knocked-in into above strains following the methods described by Tomoya Baba et al 25 . Briefly, a DNA fragment containing bla IMP-1 and CP resistance gene (cat) was amplified from the pKLC26_bla IMP-1 with primer pair of K12 genome-in pKLC26-f and K12 genome-in pKLC26 Cmr, and the PCR product was electroporated into the above E. coli cell using ELEPO 21 with the following parameters: Poring Pulse (Voltage: 2,000 V, Pulse length: 2.5 msec, Pulse interval: 50 msec, Number of pulses: 1, Polarity: +), Transfer Pulse (Voltage: 150 V, Pulse length: 50 msec, Pulse interval: 50 msec, Number of pulses: 5, Polarity: ±). After electroporation, 1 mL of SOC was added and the mixture was cultured at 37°C for 1 hour with agitation, before spreading on LB plate containing CP and further incubated at 37°C until colonies were observed. The sequence of the resulting insertion was confirmed by Sanger sequencing.
Sequence-specific bacterial killing by The logarithmic phase cultures of three E. coli strains with overexpression of bla IMP-1 , mcr-2 in plasmid and carrying control plasmid, NEB 5-alpha F'l q (pKLC26_bla IMP-1 ), and NEB 5-alpha F'l q (pKLC26_mcr-2) and NEB 5-alpha F'l q (pKLC26), in LB liquid medium were adjusted to an OD 600 of 0.1, and diluted 10 times with fresh LB medium. Transferred 300μl of each these dilutions into one tube, mixed well, then divided them into four tubes up to 100μl for each tube. Then, three tubes were treated with M13-based EC-CapsidCas13a_bla IMP-1 , EC-CapsidCas13a_mcr-2, and EC-CapsidCas13a_null (control), respectively, the remaining one tube was regarded as non-treated control. EC-CapsidCa13a treatments were carried out by individually adding 100 MOI of the above three CapsidCas13a(s) to their corresponding tubes, mixed well, then culturing at 37°C with gentle shaking for 6 hours. After incubation, 10-fold serial dilutions were made with 0.8% NaCl and colony count for calculating number of survived cells was carried out. The number of colonies formed on the agar plates containing Amp, colistin and drug-free, respectively, were counted, and cell ratios were calculated.
Sequence-specific killing activity of SA-CapsidCas13a_mecA was determined by using tetracycline (Tet) agar plate, since SA-CapsidCas13a(s) generated were carrying Tet resistance determinant delivered from SaPIbov2 during the packaging processes.
Measurement of phage titres (Transduced colony-forming units, TFU/mL)
The M13 phage/PICI-based EC-CapsidCas13a(s) were serially 10-fold diluted with SM buffer ranging from 10 -4 to 10 -7 . In the meantime, overnight culture of E. coli strain NEB 5alpha F'l q or MC1061 diluted 1: 100 with LB broth was incubated with agitation at 37°C until an OD 600 of approximately 0.1. Then, 10 µl of each dilution of M13 phage/PICI-based EC-CapsidCas13a(s) was added to 100 µl of bacterial suspension and the mixture was incubated at 37°C for 30 minutes. Subsequently, all of the culture solution was plated on LB plates containing CP or KM, and the plates were incubated overnight at 37°C. The colonies grown on the KM plate but not on the CP were counted to calculate the TFU/mL.
Detection of bacterial genes with CapsidCas13a(s)
The E. coli strains to be determined were grown to an OD 600 of about 0.5. Then, 100 µl of the culture were mixed with 3 mL molten soft agar (LB solution with 0.5% agarose) prewarmed at 50°C and pour onto an LB plate containing KM or Hygro. The plates were solidified at room temperature. Meanwhile, M13 phage/PICI-based EC-CapsidCas13a with known titres were adjusted to 10 5 TFU/mL and its 10-fold serial dilutions were prepared. Finally, 2 µL of each dilution of the M13 phage/PICI-based EC-CapsidCas13a were spotted onto the solidified soft agar and the plates were incubated at 37°C. The result was interpreted as positive if bactericidal plaque was formed on the plate. pKLC21_bla IMP-1 library sequencing The pKLC21_bla IMP-1 (CRISPR-Cas13a_bla IMP-1 expression plasmid) library targeting the whole region of bla IMP-1 were constructed as aforementioned. Equal amount of each 121 pKLC21_bla IMP-1 carrying spacers against different position of bla IMP-1 and pKLC21_null (as a control) were mixed and transformed into both E. coli MC1061(pKLC26) and MC1061(pKLC26_bla IMP-1 ). Each transformant was then plated onto 20 LB plates containing both CP and KM, and incubated at 37°C for 16 hours. After that, a total of more than 10,000 colonies for each transformant were harvested by using LB medium, and plasmids were extracted using QIAGEN Plasmid Midi Kit (QIAGEN). Plasmid sequencing was performed using Illumina MiSeq platform (2 x 301 bp) as described previously 9 .
Galleria mellonella survival assay The M-sized Galleria mellonella larvae purchased from Ikiesa company (Osaka, Japan)
were used for the survival assay to assess the effect of PICI-based EC-CapsidCas13a on treatment of E. coli infections. Upon receipt, the larvae were acclimated to the laboratory environment by leaving them in the dark room for 24 hours before starting the assay. Larvae with weak movement, dark color, unusual shape, and sizes that differ distinctly from other larvae were excluded from the experiment. Hamilton syringe (701LT, Hamilton) and a KF 731 needle (Hamilton) were used in this experiment. At first, overnight culture of carbapenemresistant E. coli R10-16 carrying carbapenem resistance gene bla IMP-1 was diluted at 1: 1000 with fresh LB medium and further incubated at 37°C with agitation to reach an OD 600 of about 0.5. The bacteria were then washed twice with PBS and adjusted to a density of approximately 1 × 10 7 CFU/mL in PBS. Twenty cream-colored larvae for each group were selected and 5 µl of bacterial suspension was directly injected into the left proleg. One hour later, 5 µl of PBS containing 100 MOI of PICI-based EC-CapsidCas13a_bla IMP-1 , EC-CapsidCas13a_null, or PBS only were injected into the same site where bacteria solution was injected. Thereafter, the larvae were transferred to a 37°C incubator, and the survival was observed up to 3 days. The larvae that did not respond to stimulation with needles or whose bodies deformed were counted as dead. Kaplan-Meier survival curves were then generated from data of three independent experiments and analyzed with log-rank test using software EZR (http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html). and the Takeda Science Foundation (SW, LC). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Contributions: KK, LC designed the study, analyzed the data, and wrote the manuscript. XT, RIC contributed to acquisition, analysis and interpretation of data, and assisted the preparation of the manuscript. JRP contributed to design of study, interpretation of data and assisted the preparation of the manuscript. All other authors contributed to data collection and interpretation, and critically revised the manuscript. All authors approved the final version of the manuscript and agreed for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
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